Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Arizona
Clinical trial register · United States · industry-sponsored

Clinical Trials in Arizona, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9125 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Oct 2026, 03:16 UTC
9125
Studies in scope
industry-sponsored, all four open statuses
4951
Recruiting now
open to new participants
2192
Lead sponsors
across recruiting studies
Top states
California 62 Florida 56 Texas 31 Arizona 30 Georgia 30
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca114 Eli Lilly and Company96 AbbVie74 Merck Sharp & Dohme LLC62 Janssen Research & Development, LLC49 Clear sponsor filter
State
California62 Florida56 Texas31 Arizona30 Georgia30
All 45 states
Target enrolment
to

Trials with a site in Arizona

30 of 9125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age
NCT07805707Influenza, Human
GlaxoSmithKline
Phase 3
54,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-09-02
Recruiting
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
NCT07585266Gastrointestinal Stromal Neoplasms
DrugsVelzatinib·Imatinib
GlaxoSmithKline
Phase 3
800
Arizona, California, Connecticut, Maryland, Nebraska, New York, Ohio, Tennessee
2026-07-27
Recruiting
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
NCT07519395Irritable Bowel Syndrome
DrugCamlipixant
GlaxoSmithKline
Phase 2
420
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-04-08
Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT07218926Gastrointestinal Neoplasms
DrugsIDRX-42·Sunitinib
GlaxoSmithKline
Phase 3
450
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Iowa
2025-12-03
Recruiting
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051Bronchiectasis
DrugGSK3862995B
GlaxoSmithKline
Phase 2
363
Alabama, Arizona, California, Colorado, Florida, Indiana, Louisiana, Maryland
2025-10-30
Recruiting
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
NCT07221227Non-alcoholic Fatty Liver Disease
DrugEfimosfermin alfa
GlaxoSmithKline
Phase 3
1,200
Arizona, Arkansas, California, Colorado, Florida, Georgia, Kansas, Louisiana
2025-10-24
Recruiting
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
NCT06990880Neoplasms, Prostate
GlaxoSmithKline
Phase 1/2
85
Arizona, Colorado, Connecticut, Minnesota, New Jersey, Tennessee
2025-06-12
Recruiting
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
NCT06847867Myelodysplastic Syndromes
DrugMomelotinib
GlaxoSmithKline
Phase 2
80
Arizona, California, Connecticut, Ohio, Texas
2025-06-05
Recruiting
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
NCT06855160Chickenpox
DrugsMarketed varicella vaccine·Hepatitis A vaccine·MMR vaccine·PCV (pneumococcal conjugate vaccine) 13
GlaxoSmithKline
Phase 3
911
Arizona, California, Florida, Idaho, Ohio, Texas, Virginia
2025-04-17
Recruiting
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
NCT06920043Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
GlaxoSmithKline
Phase 2
42
Arizona, California, Florida, Georgia, Maryland, Missouri, New York, North Carolina
2025-04-09
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Maine
2024-12-16
Recruiting
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
NCT06693895Chickenpox
DrugsMarketed varicella vaccine·Hepatitis A vaccine·PCV (pneumococcal conjugate vaccine) 13·PCV 20
GlaxoSmithKline
Phase 3
750
Arizona, California, Florida, Illinois, Kansas, Louisiana, Minnesota, Nebraska
2024-11-26
Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
NCT06613698Liver Diseases, Alcoholic
DrugGSK4532990
GlaxoSmithKline
Phase 2
393
Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana, Michigan
2024-09-27
Recruiting
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
NCT06576271Systemic Lupus Erythematosus
DrugBelimumab
GlaxoSmithKline
Phase 1
142
Arizona, Colorado, Nevada, Ohio, Oklahoma, Texas
2024-09-02
Active, closed
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
NCT06534892Respiratory Syncytial Virus Infections
DrugRSVPreF3 OA vaccine
GlaxoSmithKline
Phase 3
10,212
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas
2024-08-01
Active, closed
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249Systemic Lupus Erythematosus
DrugBelimumab
GlaxoSmithKline
Phase 4
303
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Michigan
2024-06-06
Active, closed
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837Pulmonary Disease, Chronic Obstructive
DrugGSK3862995B
GlaxoSmithKline
Phase 1
127
Arizona, Florida, Georgia, North Carolina, Oregon, Pennsylvania, South Carolina, Texas
2023-11-27
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Maryland, Michigan
2023-09-13
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200Colonic Neoplasms, Neoplasms, Colon
DrugsCapeox·Dostarlimab·Folfox
GlaxoSmithKline
Phase 3
892
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas
2023-08-01
Recruiting
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
NCT05714839Multiple Myeloma
DrugsBelantamab mafodotin·Pomalidomide·Dexamethasone
GlaxoSmithKline
Phase 1/2
123
Arizona, California, Florida, Massachusetts, Michigan, North Carolina, Ohio, Tennessee
2023-06-14
Recruiting
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
NCT05757102Asthma
DrugFF/UMEC/VI
GlaxoSmithKline
Phase 3
138
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2023-04-24
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana
2023-01-02
Active, closed
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
NCT05371080Herpes Zoster
GlaxoSmithKline
Phase 3
3,038
Arizona, Maryland, North Carolina, Pennsylvania, Tennessee, Texas, Utah
2022-08-10
Active, closed
Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
NCT05087056Meningitis, Meningococcal
GlaxoSmithKline
Phase 2
305
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Indiana, Kentucky
2021-11-18
Recruiting
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
NCT04641247Ovarian Neoplasms, Breast Neoplasms
DrugNiraparib
GlaxoSmithKline
Phase 2
37
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, New Jersey
2021-04-16
Active, closed
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
NCT04732871Respiratory Syncytial Virus Infections
GlaxoSmithKline
Phase 3
1,720
Alabama, Arizona, California, Florida, Indiana, Kansas, Minnesota, Missouri
2021-02-15
Active, closed
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623Multiple Myeloma
DrugsBelantamab mafodotin·Pomalidomide·Bortezomib·Dexamethasone
GlaxoSmithKline
Phase 3
302
Arizona, Florida, Massachusetts, Missouri, Tennessee
2020-10-01
Active, closed
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT04246047Multiple Myeloma
DrugsBelantamab mafodotin·Bortezomib·Daratumumab·Dexamethasone
GlaxoSmithKline
Phase 3
494
Arizona, Colorado, Kansas, Ohio, Texas
2020-05-07
Active, closed
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04162210Multiple Myeloma
DrugsBelantamab mafodotin·Dexamethasone
GlaxoSmithKline
Phase 3
325
Arizona, Colorado, Michigan, Nebraska, New York, Ohio, Oregon, Texas
2020-04-02
Active, closed
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
GlaxoSmithKline
Phase 2
237
Arizona, California, Colorado, Florida, Georgia, Maryland, Massachusetts, Minnesota
2018-05-03
Rows per page Showing 1–30 of 30
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/state/arizona

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,125 studies in total at the last sync on 08 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 30 of those studies with a site in Arizona that also match the filters currently applied.

How many clinical trials are recruiting in Arizona?

19 of the 30 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 11 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Arizona), 30 studies
PhaseStudiesRecruitingShare
Phase 315950%
Phase 29630%
Phase 1216.7%
Phase 1/2226.7%
Phase 2/3113.3%
Phase 4103.3%

Most active sponsors

Lead sponsors with the most studies (Arizona)
Lead sponsorStudiesRecruiting
GlaxoSmithKline3019
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.